ArticleInternational journal of clinical and experimental medicine2011
Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences.
Article in International journal of clinical and experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Targeted suppression of tumor growth by CREPT promoter-driven diphtheria toxin fragment A.Cancer gene therapy · 2026Article
- m6A Methylation-Mediated Stabilization of LINC01106 Suppresses Bladder Cancer Progression by Regulating the miR-3148/DAB1 Axis.Biomedicines · 2024Article
- Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors.Theranostics · 2023Article
- Experimental Study of Potential CD8BioMed research international · 2022Article
- LINC01106 post-transcriptionally regulates ELK3 and HOXD8 to promote bladder cancer progression.Cell death & disease · 2020Article
- Long noncoding RNAAging · 2019Article
- Targeted Diphtheria Toxin-Based Therapy: A Review Article.Frontiers in microbiology · 2019Review
- Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics.Molecular therapy. Methods & clinical development · 2018Article
- Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer.Protein & cell · 2016Article
- Regulation of lncRNA and Its Role in Cancer Metastasis.Oncology research · 2016Review
- Long Non-coding RNAs in Urologic Malignancies: Functional Roles and Clinical Translation.Journal of Cancer · 2016Review
- The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma.Oncotarget · 2015Article
- Targeted therapies in bladder cancer: an overview of in vivo research.Nature reviews. Urology · 2015Review
- Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique.Oncology letters · 2015Article
- Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Evidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.International journal of clinical and experimental medicine · 2013Article
- Emerging critical role of molecular testing in diagnostic genitourinary pathology.Archives of pathology & laboratory medicine · 2012Review
- The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis.Journal of molecular histology · 2012Article
- Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?Nature reviews. Urology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe human IGF2-P3 and IGF2-P4 promoters are highly active in bladder carcinoma, while existing at a nearly undetectable level in the surrounding normal tissue. A double promoter DTA-expressing vector was created, carrying on a single construct two separate genes expressing diphtheria toxin A-fragment (DTA), from two different regulatory sequences, selected from the cancer-specific promoters IGF2-P3 and IGF2-P4.
methodsIGF2-P3 and IGF2-P4 expression was tested in samples of urothelial carcinoma (UC) of the bladder (n=67) by RT-PCR or by ISH. The therapeutic potential of single promoter expression vectors (P3-DTA and P4-DTA) was tested and compared to the double promoter toxin vector P4-DTA-P3-DTA in UC cell lines and in heterotopic and orthotopic animal models for bladder cancer.
resultsNearly 86% of UC patients highly expressed IGF2-P4 and IGF2-P3, as determined by ISH. The double promoter vector (P4-DTA-P3-DTA) exhibited superior ability to inhibit tumor development by 68% (P=0.004) compared to the single promoter expression vectors, in heterotopic bladder tumors. The average size of the P4-DTA-P3-DTA bladder tumors (in orthotopically treated mice) was 83% smaller (P<0.001) than that of the control group.
conclusionsOverall, the double promoter vector exhibited enhanced anti-cancer activity relative to single promoter expression vectors carrying either gene alone. Our findings show that bladder tumors may be successfully treated by intravesical instillation of the double promoter vector P4-DTA-P3-DTA.
Indexed as
Identifiers
21686134PMC3113498W1534691359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.